A group of scientists at Dana-Farber Cancer Institute say they may have a lead on a pair of biomarkers that could help predict the likelihood of extending progression-free survival in multiple myeloma patients. And their work may help guide the development of future treatments.
Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in a trial update that 12 of 13 evaluable patients with advanced B cell malignancies demonstrated a complete or partial response after being treated with its chimeric antigen receptor (CAR) T cell therapy.
Many drugs used to treat lung, breast and pancreatic cancers also promote drug resistance and can ultimately spur tumor growth. Now, researchers may be able to predict which individual tumors will metastasize and spread when treated with certain drugs.
The FDA has lifted a clinical hold placed on a study at Memorial Sloan-Kettering of Juno Therapeutics' cutting-edge approach to treating cancer using genetically tailored T cells, FierceBiotech has learned.
It's not often you find a little biotech company plugging away at new cancer drugs in out-of-the-way places like Lawrence, KS. But that's just what Deciphera Pharmaceuticals has been doing.
Back in 2010, Ariad Pharmaceuticals' ridaforolimus was a promising cancer therapy worth up to $700 million in the eyes of Merck. Now, in light of an FDA rejection and some dimming development prospects, Merck has quietly washed its hands of the drug, handing it back to its former partner.
The French biotech announced this morning that it will collaborate with Paris-based Cellectis on UCART19, an engineered T cell with a chimeric antigen receptor for leukemia and lymphomas, as well as 5 other such programs. Servier is paying Cellectis $10 million down and up to $140 million per program in milestones in its gamble on the biotech's approach.
A new study out of Oregon State University has shown that a combination of mild heat and nanoparticle-delivered chemotherapy can have a whopping effect on ovarian cancer cells that have otherwise built up a resistance to cancer drugs.
Over the past two years Bayer has snagged an impressive string of key approvals for cancer and cardiovascular drugs--a much better record than many of its larger Big Pharma rivals. And today the pharma player is rolling out its slate of the next top drug prospects being groomed for late-stage pipeline work.
Almost lost in the din surrounding Merck's big about-face on the restructuring front yesterday, the pharma giant quietly posted some more promising early-stage data on what has become its brightest pipeline prospect: the cancer immunotherapy MK-3475.